US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acurx Pharmaceuticals, LLC*

5.31

+0.592712.57%

Post-market: 5.25-0.0577-1.09%17:44 EDT

Volume:76.27K

Turnover:383.99K

Market Cap:8.41M

PE:-0.39

High:5.37

Open:4.66

Low:4.59

Close:4.72

52wk High:47.60

52wk Low:3.80

Shares:1.58M

Float Shares:1.24M

Volume Ratio:1.55

T/O Rate:6.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-13.7237

EPS(LYR):-17.4507

ROE:-285.93%

ROA:-98.59%

PB:2.36

PE(LYR):-0.30

Loading ...

Overview Company News Filings

Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment

BRIEF-Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing

H.C. Wainwright Resumes Coverage with a Buy Rating on Acurx Pharmaceuticals (ACXP)

Acurx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

BRIEF-Acurx Pharmaceuticals Q1 Net Income USD -2.1 Million

Acurx Pharmaceuticals Q1 EPS $(0.11) Beats $(0.15) Estimate

Acurx Pharmaceuticals Secures New Patent from Japanese Patent Office for DNA Polymerase IIIC Inhibitors, Expanding Antibiotic Development Program

Press Release: Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Acurx Pharmaceuticals Inc expected to post a loss of 15 cents a share - Earnings Preview

BRIEF-Acurx Pharmaceuticals To Discuss First Quarter 2025 Financial Results

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach

ACCESS Newswire

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming

ACCESS Newswire

Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know

Acurx price target lowered to $5 from $14 at Alliance Global Partners

Acurx Pharmaceuticals FY 2024 GAAP EPS $(0.87) Beats $(1.52) Estimate

Acurx Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACXP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACXP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACXP\",,,,,undefined,":{"symbol":"ACXP","market":"US","secType":"STK","nameCN":"Acurx Pharmaceuticals, LLC*","latestPrice":5.3077,"timestamp":1756152000000,"preClose":4.715,"halted":0,"volume":76267,"hourTrading":{"tag":"盘后","latestPrice":5.25,"preClose":5.3077,"latestTime":"17:44 EDT","volume":73,"amount":387.6527979,"timestamp":1756158266948},"delay":0,"floatShares":1239520,"shares":1584775,"eps":-13.72374,"marketStatus":"Post-Mkt","change":0.5927,"latestTime":"08-25 18:01:10 EDT","open":4.66,"high":5.37,"low":4.5851,"amount":383994.65909100004,"amplitude":0.166469,"askPrice":5.3,"askSize":200,"bidPrice":5.06,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-13.72374,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1756166400000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.715,"preHourTrading":{"tag":"盘前","latestPrice":4.65,"preClose":4.715,"latestTime":"08:51 EDT","volume":235,"amount":1092.250014,"timestamp":1756126262602},"postHourTrading":{"tag":"盘后","latestPrice":5.25,"preClose":5.3077,"latestTime":"17:44 EDT","volume":73,"amount":387.6527979,"timestamp":1756158266948},"volumeRatio":1.54899,"impliedVol":1.1448,"impliedVolPercentile":0.6568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACXP\",,,,,undefined,":{"symbol":"ACXP","floatShares":1239520,"roa":"-98.59%","roe":"-285.93%","lyrEps":-17.4507,"volumeRatio":1.54899,"shares":1584775,"dividePrice":0,"high":5.37,"amplitude":0.166469,"preClose":4.715,"low":4.5851,"week52Low":3.8,"pbRate":"2.36","week52High":47.6,"institutionHeld":0,"latestPrice":5.3077,"committee":-0.777778,"eps":-13.72374,"divideRate":0,"volume":76267,"delay":0,"ttmEps":-13.72374,"open":4.66,"prevYearClose":16.28,"prevWeekClose":4.715,"prevMonthClose":6.52,"prevQuarterClose":10.216,"fiveDayClose":5.15,"twentyDayClose":8.16,"sixtyDayClose":7.734},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACXP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"ACXP","fiscalQuarterEnding":"2025/06","expectedEps":2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-08-05","symbol":"ACXP","defaultRemindTime":1754400600000,"type":"split","dateTimestamp":1754366400000,"forFactor":20,"toFactor":1,"ratio":20},{"date":"2025-05-13","symbol":"ACXP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.14,"defaultRemindTime":1747123200000,"name":null,"time":"Pre-Market","dateTimestamp":1747108800000,"actualEps":null},{"market":"US","date":"2025-03-18","symbol":"ACXP","fiscalQuarterEnding":"2024/12","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742270400000,"reportTimeType":"pre","actualEps":-0.38},{"date":"2024-11-13","symbol":"ACXP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/09","expectedEps":-0.23,"defaultRemindTime":1731488400000,"name":null,"time":"Pre-Market","dateTimestamp":1731474000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACXP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACXP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1742529600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACXP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACXP","date":"2025-08-22","current":-0.721155,"percent":0.929051,"low":-15.698763,"twenty":-3.963793,"median":-2.80536,"eighty":-1.724968,"high":-0.470005,"avg":-3.117744,"sd":2.254243,"marketCap":7210726},"quantilePoints":[{"date":"2021-06-11","current":-11.938223,"twenty":-11.938223,"median":-11.938223,"eighty":-11.938223,"marketCap":57246954},{"date":"2021-06-15","current":-11.938223,"twenty":-11.938223,"median":-11.938223,"eighty":-11.938223,"marketCap":57246954},{"date":"2021-06-25","current":-15.698763,"twenty":-11.938223,"median":-11.938223,"eighty":-11.938223,"marketCap":75279744},{"date":"2021-07-02","current":-12.09725,"twenty":-12.878918,"median":-11.938223,"eighty":-11.938223,"marketCap":58009530},{"date":"2021-07-09","current":-12.572868,"twenty":-12.738301,"median":-11.938223,"eighty":-11.938223,"marketCap":60290246},{"date":"2021-07-16","current":-12.469473,"twenty":-12.639041,"median":-12.076571,"eighty":-11.938223,"marketCap":59794438},{"date":"2021-07-23","current":-11.518236,"twenty":-12.560461,"median":-12.014533,"eighty":-11.866925,"marketCap":55233005},{"date":"2021-07-30","current":-11.745706,"twenty":-12.502559,"median":-11.938223,"eighty":-11.580273,"marketCap":56323783},{"date":"2021-08-06","current":-10.050023,"twenty":-12.458729,"median":-11.938223,"eighty":-11.427248,"marketCap":48192532},{"date":"2021-08-13","current":-6.159321,"twenty":-12.399613,"median":-11.893662,"eighty":-10.608357,"marketCap":48572198},{"date":"2021-08-20","current":-5.607549,"twenty":-12.287497,"median":-11.828422,"eighty":-10.06243,"marketCap":44220938},{"date":"2021-08-27","current":-6.172153,"twenty":-12.088978,"median":-11.528575,"eighty":-7.064488,"marketCap":48673390},{"date":"2021-09-03","current":-7.416849,"twenty":-12.051755,"median":-11.476878,"eighty":-6.405694,"marketCap":58489022},{"date":"2021-09-10","current":-6.41596,"twenty":-12.035212,"median":-10.897864,"eighty":-6.364632,"marketCap":50596040},{"date":"2021-09-17","current":-5.877019,"twenty":-12.014533,"median":-10.608357,"eighty":-6.364632,"marketCap":46345972},{"date":"2021-09-24","current":-5.626797,"twenty":-11.938223,"median":-10.215455,"eighty":-6.172153,"marketCap":44372727},{"date":"2021-10-01","current":-6.68543,"twenty":-11.938223,"median":-9.998325,"eighty":-6.159321,"marketCap":52721073},{"date":"2021-10-08","current":-5.248255,"twenty":-11.938223,"median":-9.863911,"eighty":-5.992506,"marketCap":41387560},{"date":"2021-10-15","current":-6.300472,"twenty":-11.938223,"median":-7.333442,"eighty":-5.979674,"marketCap":49685311},{"date":"2021-10-22","current":-6.184985,"twenty":-11.938223,"median":-6.865077,"eighty":-5.979674,"marketCap":48774582},{"date":"2021-10-29","current":-6.41596,"twenty":-11.938223,"median":-6.794501,"eighty":-5.992506,"marketCap":50596040},{"date":"2021-11-05","current":-6.852245,"twenty":-11.938223,"median":-6.865077,"eighty":-6.031002,"marketCap":54036570},{"date":"2021-11-12","current":-4.527743,"twenty":-11.849101,"median":-6.858661,"eighty":-6.031002,"marketCap":50772486},{"date":"2021-11-19","current":-4.427531,"twenty":-11.828422,"median":-6.736758,"eighty":-5.966842,"marketCap":49648749},{"date":"2021-11-26","current":-4.454861,"twenty":-11.828422,"median":-6.68543,"eighty":-5.861621,"marketCap":49955222},{"date":"2021-12-03","current":-3.780711,"twenty":-11.762249,"median":-6.614854,"eighty":-5.699938,"marketCap":42395536},{"date":"2021-12-10","current":-3.835372,"twenty":-11.580273,"median":-6.557111,"eighty":-5.569053,"marketCap":43008484},{"date":"2021-12-17","current":-4.035795,"twenty":-11.522372,"median":-6.505783,"eighty":-5.166131,"marketCap":45255958},{"date":"2021-12-23","current":-4.32732,"twenty":-11.493421,"median":-6.428792,"eighty":-4.527743,"marketCap":48525012},{"date":"2021-12-31","current":-3.936859,"twenty":-11.476878,"median":-6.41596,"eighty":-4.409311,"marketCap":44146523},{"date":"2022-01-07","current":-4.017574,"twenty":-11.439656,"median":-6.358216,"eighty":-4.32732,"marketCap":45051642},{"date":"2022-01-14","current":-4.172447,"twenty":-11.104655,"median":-6.313304,"eighty":-4.289057,"marketCap":46788327},{"date":"2022-01-21","current":-3.316093,"twenty":-10.839963,"median":-6.223481,"eighty":-4.21982,"marketCap":37185482},{"date":"2022-01-28","current":-3.534737,"twenty":-10.695209,"median":-6.172153,"eighty":-4.137828,"marketCap":39637272},{"date":"2022-02-04","current":-3.589398,"twenty":-10.608357,"median":-6.159321,"eighty":-4.074057,"marketCap":40250220},{"date":"2022-02-11","current":-3.71694,"twenty":-10.550456,"median":-6.063082,"eighty":-4.024862,"marketCap":41680431},{"date":"2022-02-18","current":-3.73516,"twenty":-10.364344,"median":-5.979674,"eighty":-3.984778,"marketCap":41884747},{"date":"2022-02-25","current":-3.252322,"twenty":-10.194776,"median":-5.966842,"eighty":-3.953804,"marketCap":36470377},{"date":"2022-03-04","current":-3.252322,"twenty":-10.099653,"median":-5.896267,"eighty":-3.859058,"marketCap":36470377},{"date":"2022-03-11","current":-3.644059,"twenty":-10.029344,"median":-5.787196,"eighty":-3.791643,"marketCap":40863168},{"date":"2022-03-18","current":-2.922007,"twenty":-9.942491,"median":-5.68454,"eighty":-3.755202,"marketCap":37248855},{"date":"2022-03-25","current":-2.838922,"twenty":-9.913541,"median":-5.607549,"eighty":-3.720584,"marketCap":36189718},{"date":"2022-04-01","current":-2.737374,"twenty":-9.379631,"median":-5.44715,"eighty":-3.682321,"marketCap":34895218},{"date":"2022-04-08","current":-2.881869,"twenty":-7.43738,"median":-5.248255,"eighty":-3.645881,"marketCap":36737195},{"date":"2022-04-14","current":-3.210996,"twenty":-7.416849,"median":-4.609734,"eighty":-3.634948,"marketCap":40932808},{"date":"2022-04-22","current":-3.210996,"twenty":-7.250034,"median":-4.504968,"eighty":-3.534737,"marketCap":40932808},{"date":"2022-04-29","current":-3.003032,"twenty":-7.237203,"median":-4.427531,"eighty":-3.388974,"marketCap":38281743},{"date":"2022-05-06","current":-3.123797,"twenty":-7.121715,"median":-4.35465,"eighty":-3.315273,"marketCap":39821223},{"date":"2022-05-13","current":-1.994712,"twenty":-7.044724,"median":-4.32732,"eighty":-3.252322,"marketCap":27813277},{"date":"2022-05-20","current":-1.943188,"twenty":-7.01906,"median":-4.318209,"eighty":-3.210996,"marketCap":27094853},{"date":"2022-05-27","current":-1.923388,"twenty":-6.993396,"median":-4.236218,"eighty":-3.146776,"marketCap":26818773},{"date":"2022-06-03","current":-1.880623,"twenty":-6.942068,"median":-4.208888,"eighty":-3.079156,"marketCap":26222481},{"date":"2022-06-10","current":-2.774931,"twenty":-6.918971,"median":-4.158782,"eighty":-3.024918,"marketCap":38692271},{"date":"2022-06-17","current":-2.679244,"twenty":-6.906139,"median":-4.117786,"eighty":-2.999671,"marketCap":37358055},{"date":"2022-06-24","current":-2.716047,"twenty":-6.880475,"median":-4.090456,"eighty":-2.939922,"marketCap":37871215},{"date":"2022-07-01","current":-2.76021,"twenty":-6.857378,"median":-4.044905,"eighty":-2.90143,"marketCap":38487007},{"date":"2022-07-08","current":-2.760137,"twenty":-6.852245,"median":-4.026684,"eighty":-2.848154,"marketCap":38485981},{"date":"2022-07-15","current":-2.668203,"twenty":-6.80605,"median":-4.008464,"eighty":-2.820986,"marketCap":37204107},{"date":"2022-07-22","current":-2.657162,"twenty":-6.72136,"median":-3.972024,"eighty":-2.802901,"marketCap":37050159},{"date":"2022-07-29","current":-2.635081,"twenty":-6.693129,"median":-3.953804,"eighty":-2.779424,"marketCap":36742263},{"date":"2022-08-05","current":-2.88534,"twenty":-6.68543,"median":-3.921918,"eighty":-2.779424,"marketCap":40231751},{"date":"2022-08-12","current":-3.956018,"twenty":-6.664899,"median":-3.844482,"eighty":-2.782292,"marketCap":49687496},{"date":"2022-08-19","current":-3.519492,"twenty":-6.618704,"median":-3.839927,"eighty":-2.785236,"marketCap":44204738},{"date":"2022-08-26","current":-3.110248,"twenty":-6.585341,"median":-3.798931,"eighty":-2.789652,"marketCap":39064652},{"date":"2022-09-02","current":-3.073871,"twenty":-6.56481,"median":-3.780666,"eighty":-2.792596,"marketCap":38607755},{"date":"2022-09-09","current":-3.965112,"twenty":-6.551978,"median":-3.772829,"eighty":-2.798485,"marketCap":49801720},{"date":"2022-09-16","current":-3.542438,"twenty":-6.531447,"median":-3.78062,"eighty":-2.805846,"marketCap":44492944},{"date":"2022-09-23","current":-2.787945,"twenty":-6.521181,"median":-3.757935,"eighty":-2.805846,"marketCap":35016525},{"date":"2022-09-30","current":-2.760341,"twenty":-6.47242,"median":-3.73516,"eighty":-2.805846,"marketCap":34669827},{"date":"2022-10-07","current":-3.128387,"twenty":-6.436491,"median":-3.71694,"eighty":-2.811734,"marketCap":39292470},{"date":"2022-10-14","current":-2.714336,"twenty":-6.41596,"median":-3.689609,"eighty":-2.811734,"marketCap":34091996},{"date":"2022-10-21","current":-2.806347,"twenty":-6.41596,"median":-3.672742,"eighty":-2.791124,"marketCap":35247657},{"date":"2022-10-28","current":-3.027174,"twenty":-6.413394,"median":-3.653169,"eighty":-2.791124,"marketCap":38021243},{"date":"2022-11-04","current":-2.723537,"twenty":-6.395429,"median":-3.644059,"eighty":-2.783423,"marketCap":34207562},{"date":"2022-11-11","current":-2.94384,"twenty":-6.362066,"median":-3.619529,"eighty":-2.778468,"marketCap":33734492},{"date":"2022-11-18","current":-3.196747,"twenty":-6.346667,"median":-3.595377,"eighty":-2.782292,"marketCap":36632644},{"date":"2022-11-25","current":-2.953956,"twenty":-6.326136,"median":-3.588921,"eighty":-2.782292,"marketCap":33850418},{"date":"2022-12-02","current":-3.338375,"twenty":-6.313304,"median":-3.534737,"eighty":-2.787945,"marketCap":38255609},{"date":"2022-12-09","current":-3.743026,"twenty":-6.300472,"median":-3.538588,"eighty":-2.789652,"marketCap":42892653},{"date":"2022-12-16","current":-3.874538,"twenty":-6.223481,"median":-3.589398,"eighty":-2.789652,"marketCap":44399692},{"date":"2022-12-23","current":-3.975701,"twenty":-6.184985,"median":-3.603063,"eighty":-2.797013,"marketCap":45558953},{"date":"2022-12-30","current":-4.026282,"twenty":-6.174719,"median":-3.62058,"eighty":-2.802902,"marketCap":46138583},{"date":"2023-01-06","current":-4.501748,"twenty":-6.172153,"median":-3.638406,"eighty":-2.805558,"marketCap":51587110},{"date":"2023-01-13","current":-4.299422,"twenty":-6.164454,"median":-3.644059,"eighty":-2.809579,"marketCap":49268588},{"date":"2023-01-20","current":-4.258957,"twenty":-6.159321,"median":-3.653169,"eighty":-2.811734,"marketCap":48804883},{"date":"2023-01-27","current":-3.884654,"twenty":-6.149055,"median":-3.672742,"eighty":-2.8141,"marketCap":44515618},{"date":"2023-02-03","current":-3.540701,"twenty":-6.118259,"median":-3.662279,"eighty":-2.817733,"marketCap":40574131},{"date":"2023-02-10","current":-3.540701,"twenty":-6.069498,"median":-3.644059,"eighty":-2.819825,"marketCap":40574131},{"date":"2023-02-17","current":-3.70246,"twenty":-6.015604,"median":-3.644059,"eighty":-2.823936,"marketCap":42427789},{"date":"2023-02-24","current":-3.287793,"twenty":-5.98994,"median":-3.641863,"eighty":-2.825677,"marketCap":37675979},{"date":"2023-03-03","current":-3.641863,"twenty":-5.979674,"median":-3.638406,"eighty":-2.827332,"marketCap":41733392},{"date":"2023-03-10","current":-3.469887,"twenty":-5.977108,"median":-3.621631,"eighty":-2.83395,"marketCap":39762648},{"date":"2023-03-17","current":-3.021341,"twenty":-5.959143,"median":-3.604508,"eighty":-2.834944,"marketCap":36536396},{"date":"2023-03-24","current":-3.406225,"twenty":-5.925781,"median":-3.592246,"eighty":-2.839484,"marketCap":41190714},{"date":"2023-03-31","current":-3.329248,"twenty":-5.907816,"median":-3.59034,"eighty":-2.843856,"marketCap":40259850},{"date":"2023-04-06","current":-3.396603,"twenty":-5.877019,"median":-3.579746,"eighty":-2.852353,"marketCap":41074356},{"date":"2023-04-14","current":-2.751922,"twenty":-5.800028,"median":-3.550817,"eighty":-2.852353,"marketCap":33278373},{"date":"2023-04-21","current":-2.97323,"twenty":-5.787196,"median":-3.550817,"eighty":-2.848143,"marketCap":35954606},{"date":"2023-04-28","current":-2.866607,"twenty":-5.735868,"median":-3.540701,"eighty":-2.852353,"marketCap":34665231},{"date":"2023-05-05","current":-2.827999,"twenty":-5.710204,"median":-3.534737,"eighty":-2.841732,"marketCap":34198359},{"date":"2023-05-12","current":-3.19477,"twenty":-5.669142,"median":-3.525038,"eighty":-2.846189,"marketCap":38633641},{"date":"2023-05-19","current":-2.850337,"twenty":-5.633213,"median":-3.510352,"eighty":-2.847975,"marketCap":35132102},{"date":"2023-05-26","current":-2.937567,"twenty":-5.611399,"median":-3.474945,"eighty":-2.849898,"marketCap":36207255},{"date":"2023-06-02","current":-2.937567,"twenty":-5.59985,"median":-3.447184,"eighty":-2.851547,"marketCap":36207255},{"date":"2023-06-09","current":-2.808114,"twenty":-5.517726,"median":-3.439538,"eighty":-2.851547,"marketCap":34611681},{"date":"2023-06-16","current":-2.738409,"twenty":-5.4433,"median":-3.429421,"eighty":-2.847807,"marketCap":33752526},{"date":"2023-06-23","current":-2.569126,"twenty":-5.402238,"median":-3.402649,"eighty":-2.838681,"marketCap":31666006},{"date":"2023-06-30","current":-2.68862,"twenty":-5.340645,"median":-3.397344,"eighty":-2.829189,"marketCap":33138844},{"date":"2023-07-07","current":-2.540461,"twenty":-5.248255,"median":-3.388974,"eighty":-2.822775,"marketCap":31312689},{"date":"2023-07-14","current":-2.40399,"twenty":-4.837634,"median":-3.364889,"eighty":-2.811734,"marketCap":29630603},{"date":"2023-07-21","current":-2.361999,"twenty":-4.609734,"median":-3.350513,"eighty":-2.798157,"marketCap":29113038},{"date":"2023-07-28","current":-1.847608,"twenty":-4.542213,"median":-3.33875,"eighty":-2.787945,"marketCap":22772865},{"date":"2023-08-04","current":-2.21503,"twenty":-4.527743,"median":-3.338375,"eighty":-2.777512,"marketCap":27301560},{"date":"2023-08-11","current":-1.900097,"twenty":-4.527743,"median":-3.329248,"eighty":-2.760341,"marketCap":23419821},{"date":"2023-08-18","current":-1.869135,"twenty":-4.501748,"median":-3.318884,"eighty":-2.76021,"marketCap":24579691},{"date":"2023-08-25","current":-2.017479,"twenty":-4.482192,"median":-3.315273,"eighty":-2.741939,"marketCap":26530461},{"date":"2023-09-01","current":-1.908693,"twenty":-4.454861,"median":-3.304204,"eighty":-2.73148,"marketCap":25099897},{"date":"2023-09-08","current":-1.75046,"twenty":-4.432997,"median":-3.297891,"eighty":-2.723392,"marketCap":23019076},{"date":"2023-09-15","current":-1.710901,"twenty":-4.39109,"median":-3.28304,"eighty":-2.713206,"marketCap":22498871},{"date":"2023-09-22","current":-1.582336,"twenty":-4.374692,"median":-3.266474,"eighty":-2.696583,"marketCap":20808204},{"date":"2023-09-29","current":-1.463661,"twenty":-4.343718,"median":-3.252322,"eighty":-2.679128,"marketCap":19247589},{"date":"2023-10-06","current":-1.542778,"twenty":-4.329142,"median":-3.235119,"eighty":-2.671147,"marketCap":20287999},{"date":"2023-10-13","current":-4.034958,"twenty":-4.32732,"median":-3.237569,"eighty":-2.671147,"marketCap":53060922},{"date":"2023-10-20","current":-4.964581,"twenty":-4.374692,"median":-3.256877,"eighty":-2.671883,"marketCap":65285742},{"date":"2023-10-27","current":-4.667893,"twenty":-4.397094,"median":-3.266474,"eighty":-2.673013,"marketCap":61384204},{"date":"2023-11-03","current":-3.758049,"twenty":-4.476726,"median":-3.28304,"eighty":-2.677757,"marketCap":49419486},{"date":"2023-11-10","current":-3.708601,"twenty":-4.449395,"median":-3.283194,"eighty":-2.678778,"marketCap":48769230},{"date":"2023-11-17","current":-3.917109,"twenty":-4.422199,"median":-3.297873,"eighty":-2.680716,"marketCap":49840076},{"date":"2023-11-24","current":-4.187628,"twenty":-4.400873,"median":-3.300382,"eighty":-2.686605,"marketCap":53282070},{"date":"2023-12-01","current":-3.808902,"twenty":-4.38198,"median":-3.312639,"eighty":-2.68862,"marketCap":48463279},{"date":"2023-12-08","current":-4.696202,"twenty":-4.38198,"median":-3.318142,"eighty":-2.693965,"marketCap":59753020},{"date":"2023-12-15","current":-3.63577,"twenty":-4.37287,"median":-3.328111,"eighty":-2.697237,"marketCap":46260402},{"date":"2023-12-22","current":-3.884647,"twenty":-4.343718,"median":-3.333812,"eighty":-2.703555,"marketCap":49427037},{"date":"2023-12-29","current":-4.295835,"twenty":-4.333177,"median":-3.338375,"eighty":-2.706495,"marketCap":54658868},{"date":"2024-01-05","current":-4.285014,"twenty":-4.33643,"median":-3.338563,"eighty":-2.708536,"marketCap":54521188},{"date":"2024-01-12","current":-5.204777,"twenty":-4.400873,"median":-3.348492,"eighty":-2.708686,"marketCap":66223969},{"date":"2024-01-19","current":-4.328297,"twenty":-4.440176,"median":-3.358415,"eighty":-2.713206,"marketCap":55071908},{"date":"2024-01-26","current":-4.317476,"twenty":-4.429326,"median":-3.377159,"eighty":-2.715705,"marketCap":54934228},{"date":"2024-02-02","current":-3.527562,"twenty":-4.406205,"median":-3.396603,"eighty":-2.721877,"marketCap":44883605},{"date":"2024-02-09","current":-3.321968,"twenty":-4.385759,"median":-3.397158,"eighty":-2.723334,"marketCap":42267689},{"date":"2024-02-16","current":-3.300327,"twenty":-4.374692,"median":-3.388974,"eighty":-2.723392,"marketCap":41992329},{"date":"2024-02-23","current":-3.386893,"twenty":-4.359111,"median":-3.386893,"eighty":-2.723485,"marketCap":43093768},{"date":"2024-03-01","current":-3.105553,"twenty":-4.341834,"median":-3.386893,"eighty":-2.727023,"marketCap":39514093},{"date":"2024-03-08","current":-3.213761,"twenty":-4.33155,"median":-3.364889,"eighty":-2.730627,"marketCap":40890891},{"date":"2024-03-15","current":-2.932421,"twenty":-4.328297,"median":-3.350513,"eighty":-2.735016,"marketCap":37311217},{"date":"2024-03-22","current":-2.226653,"twenty":-4.328297,"median":-3.33875,"eighty":-2.723485,"marketCap":32459630},{"date":"2024-03-28","current":-2.518496,"twenty":-4.327906,"median":-3.338375,"eighty":-2.718962,"marketCap":36714047},{"date":"2024-04-05","current":-2.118563,"twenty":-4.32732,"median":-3.329248,"eighty":-2.706495,"marketCap":30883919},{"date":"2024-04-12","current":-2.021282,"twenty":-4.323676,"median":-3.321968,"eighty":-2.687411,"marketCap":29465780},{"date":"2024-04-19","current":-2.302316,"twenty":-4.318209,"median":-3.318884,"eighty":-2.674142,"marketCap":33562627},{"date":"2024-04-26","current":-2.183417,"twenty":-4.318209,"median":-3.315273,"eighty":-2.664523,"marketCap":31829346},{"date":"2024-05-03","current":-2.301105,"twenty":-4.317916,"median":-3.304204,"eighty":-2.652746,"marketCap":33544976},{"date":"2024-05-10","current":-2.192562,"twenty":-4.316324,"median":-3.29791,"eighty":-2.63511,"marketCap":31962666},{"date":"2024-05-17","current":-2.129106,"twenty":-4.308527,"median":-3.285571,"eighty":-2.616729,"marketCap":34177900},{"date":"2024-05-24","current":-2.57267,"twenty":-4.299422,"median":-3.281137,"eighty":-2.577025,"marketCap":41298296},{"date":"2024-05-31","current":-2.477227,"twenty":-4.298705,"median":-3.261432,"eighty":-2.56885,"marketCap":39766186},{"date":"2024-06-07","current":-2.368663,"twenty":-4.295086,"median":-3.249273,"eighty":-2.539607,"marketCap":38023444},{"date":"2024-06-14","current":-2.398272,"twenty":-4.291572,"median":-3.237569,"eighty":-2.530033,"marketCap":38498737},{"date":"2024-06-21","current":-2.299577,"twenty":-4.289508,"median":-3.235402,"eighty":-2.519465,"marketCap":36914427},{"date":"2024-06-28","current":-2.220622,"twenty":-4.285014,"median":-3.234651,"eighty":-2.502591,"marketCap":35646979},{"date":"2024-07-05","current":-2.033103,"twenty":-4.280355,"median":-3.233027,"eighty":-2.482891,"marketCap":32636790},{"date":"2024-07-12","current":-2.279839,"twenty":-4.271096,"median":-3.223405,"eighty":-2.467358,"marketCap":36597565},{"date":"2024-07-19","current":-2.398272,"twenty":-4.264513,"median":-3.212378,"eighty":-2.463479,"marketCap":38498737},{"date":"2024-07-26","current":-2.25023,"twenty":-4.25984,"median":-3.210996,"eighty":-2.445645,"marketCap":36122272},{"date":"2024-08-02","current":-2.08245,"twenty":-4.250864,"median":-3.208522,"eighty":-2.402846,"marketCap":33428945},{"date":"2024-08-09","current":-1.825588,"twenty":-4.246031,"median":-3.202969,"eighty":-2.384084,"marketCap":30540786},{"date":"2024-08-16","current":-1.951826,"twenty":-4.23804,"median":-3.197661,"eighty":-2.361358,"marketCap":32652648},{"date":"2024-08-23","current":-2.204301,"twenty":-4.236218,"median":-3.19477,"eighty":-2.345346,"marketCap":36876374},{"date":"2024-08-30","current":-2.136326,"twenty":-4.223316,"median":-3.188517,"eighty":-2.302074,"marketCap":35739217},{"date":"2024-09-06","current":-1.922694,"twenty":-4.219131,"median":-3.172148,"eighty":-2.286104,"marketCap":32165296},{"date":"2024-09-13","current":-1.980957,"twenty":-4.218492,"median":-3.165041,"eighty":-2.275891,"marketCap":33140001},{"date":"2024-09-20","current":-1.951826,"twenty":-4.21273,"median":-3.15797,"eighty":-2.265537,"marketCap":32652648},{"date":"2024-09-27","current":-1.86443,"twenty":-4.202511,"median":-3.146776,"eighty":-2.257421,"marketCap":31190590},{"date":"2024-10-04","current":-2.087774,"twenty":-4.19188,"median":-3.130117,"eighty":-2.249446,"marketCap":34926962},{"date":"2024-10-11","current":-2.010089,"twenty":-4.187628,"median":-3.128387,"eighty":-2.234788,"marketCap":33627354},{"date":"2024-10-18","current":-1.951826,"twenty":-4.187628,"median":-3.113033,"eighty":-2.220622,"marketCap":32652648},{"date":"2024-10-25","current":-1.786746,"twenty":-4.178519,"median":-3.10794,"eighty":-2.213319,"marketCap":29890982},{"date":"2024-11-01","current":-1.806167,"twenty":-4.166981,"median":-3.100143,"eighty":-2.203947,"marketCap":30215884},{"date":"2024-11-08","current":-1.806167,"twenty":-4.157871,"median":-3.088695,"eighty":-2.19356,"marketCap":30215884},{"date":"2024-11-15","current":-1.767787,"twenty":-4.150298,"median":-3.081142,"eighty":-2.181144,"marketCap":29055182},{"date":"2024-11-22","current":-1.387508,"twenty":-4.135209,"median":-3.07318,"eighty":-2.149641,"marketCap":22804939},{"date":"2024-11-29","current":-1.284729,"twenty":-4.125219,"median":-3.065235,"eighty":-2.140727,"marketCap":21115685},{"date":"2024-12-06","current":-0.770838,"twenty":-4.120736,"median":-3.05063,"eighty":-2.136326,"marketCap":12669411},{"date":"2024-12-13","current":-0.878858,"twenty":-4.111282,"median":-3.042419,"eighty":-2.129883,"marketCap":14444817},{"date":"2024-12-20","current":-0.847921,"twenty":-4.10134,"median":-3.035027,"eighty":-2.112058,"marketCap":13936352},{"date":"2024-12-27","current":-0.918838,"twenty":-4.100763,"median":-3.029808,"eighty":-2.097994,"marketCap":15101937},{"date":"2025-01-03","current":-0.914624,"twenty":-4.099566,"median":-3.026769,"eighty":-2.087774,"marketCap":15032678},{"date":"2025-01-10","current":-0.830655,"twenty":-4.092278,"median":-3.023853,"eighty":-2.081672,"marketCap":13652557},{"date":"2025-01-17","current":-0.907533,"twenty":-4.090284,"median":-3.019134,"eighty":-2.067585,"marketCap":14916119},{"date":"2025-01-24","current":-0.895816,"twenty":-4.090241,"median":-3.010309,"eighty":-2.058642,"marketCap":14723544},{"date":"2025-01-31","current":-0.750899,"twenty":-4.090241,"median":-2.997753,"eighty":-2.043977,"marketCap":12341695},{"date":"2025-02-07","current":-0.795813,"twenty":-4.088284,"median":-2.986227,"eighty":-2.027397,"marketCap":13079899},{"date":"2025-02-14","current":-0.762615,"twenty":-4.072667,"median":-2.973442,"eighty":-2.016716,"marketCap":12534270},{"date":"2025-02-21","current":-0.804343,"twenty":-4.056659,"median":-2.970335,"eighty":-2.010243,"marketCap":13220108},{"date":"2025-02-28","current":-0.729212,"twenty":-4.04696,"median":-2.964072,"eighty":-1.994631,"marketCap":11985262},{"date":"2025-03-07","current":-0.470005,"twenty":-4.046781,"median":-2.953761,"eighty":-1.988678,"marketCap":7724962},{"date":"2025-03-14","current":-0.534112,"twenty":-4.045871,"median":-2.953473,"eighty":-1.982077,"marketCap":8778614},{"date":"2025-03-21","current":-0.661755,"twenty":-4.044905,"median":-2.944364,"eighty":-1.980421,"marketCap":9332799},{"date":"2025-03-28","current":-0.638311,"twenty":-4.041261,"median":-2.937567,"eighty":-1.964134,"marketCap":9002161},{"date":"2025-04-04","current":-0.500145,"twenty":-4.03546,"median":-2.933581,"eighty":-1.951826,"marketCap":7053603},{"date":"2025-04-11","current":-0.553755,"twenty":-4.032484,"median":-2.92512,"eighty":-1.947591,"marketCap":7809661},{"date":"2025-04-17","current":-0.58267,"twenty":-4.028274,"median":-2.922007,"eighty":-1.938558,"marketCap":8217448},{"date":"2025-04-25","current":-0.632371,"twenty":-4.026282,"median":-2.909973,"eighty":-1.922833,"marketCap":8918399},{"date":"2025-05-02","current":-0.645031,"twenty":-4.026089,"median":-2.905875,"eighty":-1.915453,"marketCap":9096944},{"date":"2025-05-09","current":-0.562664,"twenty":-4.023768,"median":-2.898358,"eighty":-1.909551,"marketCap":7935303},{"date":"2025-05-16","current":-0.71839,"twenty":-4.016958,"median":-2.893258,"eighty":-1.899063,"marketCap":8530451},{"date":"2025-05-23","current":-0.73918,"twenty":-4.01329,"median":-2.887777,"eighty":-1.872577,"marketCap":8777327},{"date":"2025-05-30","current":-0.717833,"twenty":-4.008464,"median":-2.885625,"eighty":-1.86443,"marketCap":8523839},{"date":"2025-06-06","current":-0.687081,"twenty":-4.008464,"median":-2.879956,"eighty":-1.85472,"marketCap":8158684},{"date":"2025-06-13","current":-0.652772,"twenty":-4.00605,"median":-2.871746,"eighty":-1.84598,"marketCap":7751278},{"date":"2025-06-20","current":-1.423798,"twenty":-4.00415,"median":-2.862255,"eighty":-1.845009,"marketCap":16906756},{"date":"2025-06-27","current":-0.947419,"twenty":-4.003675,"median":-2.857787,"eighty":-1.834155,"marketCap":11250037},{"date":"2025-07-03","current":-0.953154,"twenty":-3.997446,"median":-2.850337,"eighty":-1.826753,"marketCap":11318134},{"date":"2025-07-11","current":-0.986771,"twenty":-3.99303,"median":-2.844518,"eighty":-1.817857,"marketCap":11717321},{"date":"2025-07-18","current":-1.111951,"twenty":-3.991288,"median":-2.838521,"eighty":-1.811994,"marketCap":13203761},{"date":"2025-07-25","current":-1.094616,"twenty":-3.985317,"median":-2.830974,"eighty":-1.796456,"marketCap":12997912},{"date":"2025-08-01","current":-0.807341,"twenty":-3.981494,"median":-2.825677,"eighty":-1.786746,"marketCap":9586695},{"date":"2025-08-08","current":-0.602367,"twenty":-3.977874,"median":-2.817754,"eighty":-1.767581,"marketCap":7152755},{"date":"2025-08-15","current":-0.770288,"twenty":-3.969348,"median":-2.811734,"eighty":-1.75046,"marketCap":7702006},{"date":"2025-08-22","current":-0.721155,"twenty":-3.963793,"median":-2.80536,"eighty":-1.724968,"marketCap":7210726}],"updateTime":1756159270397},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACXP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542389791","title":"Acurx Pharmaceuticals Announces Advancement of Ibezapolstat to Phase 3 Clinical Trials for C. difficile Infection Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2542389791","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542389791?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:30","pubTimestamp":1749468643,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. has announced the advancement of its lead antibiotic candidate, ibezapolstat, to international pivotal Phase 3 clinical trials for the treatment of C. difficile infection . The company has been working in collaboration with Leiden University Medical Center  to study the mechanism of action of DNA pol IIIC inhibitors. Results from this collaboration were presented at a scientific conference on May 21 by Dr. Mia Urem from LUMC. These findings provide insight into the structural biology of DNA pol IIIC in complex with inhibitors, which is crucial for developing this new class of antibiotics aimed at treating resistant gram-positive infections. Acurx's Executive Chairman, Bob DeLuccia, emphasized the importance of these data in guiding the design of new compounds to combat antimicrobial resistance. Further details of the presentation are available on the company's website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL3JvQsf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"2537951348","title":"BRIEF-Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537951348","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537951348?lang=en_us&edition=fundamental","pubTime":"2025-05-22 04:40","pubTimestamp":1747860008,"startTime":"0","endTime":"0","summary":"BRIEF-Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling Stockholder - SEC FilingAcurx Pharmaceuticals Inc ACXP.O:ACURX PHARMACEUTICALS INC FILES FOR RESALE OF UP TO 10.9 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDER - SEC FILINGSource text: [ID:n0001104659-25-051615]Further company coverage: ACXP.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RT2WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4563","ACXP","BK4139"],"gpt_icon":0},{"id":"2536158020","title":"H.C. Wainwright Resumes Coverage with a Buy Rating on Acurx Pharmaceuticals (ACXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2536158020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536158020?lang=en_us&edition=fundamental","pubTime":"2025-05-18 01:37","pubTimestamp":1747503466,"startTime":"0","endTime":"0","summary":"In a report released on May 15, Matthew Keller from H.C. Wainwright resumed coverage with a Buy rating on Acurx Pharmaceuticals (ACXP – Research Re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-resumes-coverage-with-a-buy-rating-on-acurx-pharmaceuticals-acxp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-resumes-coverage-with-a-buy-rating-on-acurx-pharmaceuticals-acxp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACXP"],"gpt_icon":0},{"id":"2535779244","title":"Acurx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535779244","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535779244?lang=en_us&edition=fundamental","pubTime":"2025-05-13 21:31","pubTimestamp":1747143103,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryAcurx Pharmaceuticals Inc ACXP.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nL8N3RL1KO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP"],"gpt_icon":0},{"id":"2535724602","title":"BRIEF-Acurx Pharmaceuticals Q1 Net Income USD -2.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535724602","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535724602?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:40","pubTimestamp":1747136447,"startTime":"0","endTime":"0","summary":"BRIEF-Acurx Pharmaceuticals Q1 Net Income USD -2.1 MillionMay 13 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O:ACURX PHARMACEUTICALS Q1 NET INCOME USD -2.1 MILLIONSource text: ID:nPn75ZGfmaFurther company coverage: ACXP.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nPLXB34E92:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ACXP","BK4563"],"gpt_icon":0},{"id":"2535882726","title":"Acurx Pharmaceuticals Q1 EPS $(0.11) Beats $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535882726","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535882726?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:03","pubTimestamp":1747134187,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Q1 EPS $(0.11) Beats $(0.15) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45371284/acurx-pharmaceuticals-q1-eps-0-11-beats-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP"],"gpt_icon":0},{"id":"2535146725","title":"Acurx Pharmaceuticals Secures New Patent from Japanese Patent Office for DNA Polymerase IIIC Inhibitors, Expanding Antibiotic Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2535146725","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535146725?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:01","pubTimestamp":1747134103,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Secures New Patent from Japanese Patent Office for DNA Polymerase IIIC Inhibitors, Expanding Antibiotic Development Program. Acurx Pharmaceuticals has been granted a new patent by the Japanese Patent Office for its DNA polymerase IIIC inhibitors, which target the treatment of MRSA, VRE, and Anthrax infections. This patent is set to expire in December 2039, subject to extension, and represents a significant advancement in the ongoing development of their pre-clinical antibiotic candidate, ACX-375C.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire  on May 13, 2025, and is solely responsible for the information co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL1s0hyS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","ACXP","BK4539"],"gpt_icon":0},{"id":"2535567726","title":"Press Release: Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535567726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535567726?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:01","pubTimestamp":1747134060,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025.Highlights of the first quarter ended March 31, 2025, or in some cases shortly thereafter, include:. -- In January 2025, the Company announced it had closed a $2.5 million. registered direct offering priced at the market under Nasdaq rules.-- Also in January 2025, we announced that we received positive regulatory. guidance from the European Medicines Agency  for the ibezapolstat.  Phase 3 clinical trial program, which is aligned with FDA on. matters of manufacturing, non-clinical and clinical aspects of the Phase. 3 program. The EMA guidance also confirmed ibezapolstat's regulatory. pathway for a Marketing Authorization Application to be filed by the. Company after successful completion ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800965.SGD","LU1989771016.USD","LU0048573561.USD","FDX","LU0251142724.SGD","BK4139","BK4131","LU1571399168.USD","BK4533","BK4585","BK4563","BK4135","BK4162","BK4539","BK4022","BK4194","ACXP","MET","BK4588","LU0128525689.USD","NCI","BK4202","BK4232","R","LU1291159041.SGD","LU1496350502.SGD","LU0052756011.USD","LU0742534661.SGD","LU1267930227.SGD","GAIN","LU1989772840.SGD","VRE","LU1989772923.USD","LU0251131958.USD"],"gpt_icon":0},{"id":"2534317404","title":"Acurx Pharmaceuticals Inc  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534317404","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534317404?lang=en_us&edition=fundamental","pubTime":"2025-05-09 23:24","pubTimestamp":1746804250,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc  expected to post a loss of15cents a share - Earnings Preview Acurx Pharmaceuticals Inc ACXP.OQ ACXP.O is expected to show no change in quarterly revenue when it reports  res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH2H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP"],"gpt_icon":0},{"id":"2531034014","title":"BRIEF-Acurx Pharmaceuticals To Discuss First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531034014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531034014?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:41","pubTimestamp":1746016883,"startTime":"0","endTime":"0","summary":"BRIEF-Acurx Pharmaceuticals To Discuss First Quarter 2025 Financial Results April 30 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O:ACURX PHARMACEUTICALS TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA1QCYYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4563","ACXP","BK4139"],"gpt_icon":0},{"id":"2531756035","title":"Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2531756035","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531756035?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:. International: Click here for participant international Toll-Free access numbers. Acurx previously announced that it had received positive regulatory guidance from the EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC  information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application  for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details on Acurx's two planned international Phase 3 clinical trials, 1:1 randomized , primary and secondary endpoints, sample size, statistical analysis plan and the overall registration sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acurx-pharmaceuticals-discuss-first-quarter-113000266.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-pharmaceuticals-discuss-first-quarter-113000266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4215","ACXP","GAIN","BK4563","BK4194","BK4539","BK4139","VRE","MAA","BK4135","BK4588","BK4585"],"gpt_icon":0},{"id":"2530692470","title":"Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase","url":"https://stock-news.laohu8.com/highlight/detail?id=2530692470","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530692470?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals  , a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase on Wednesday, May 21, 2025, at 9:00 a.m. ET. The Company's lead antibiotic candidate, ibezapolstat , is ready to advance to international Phase 3 clinical trials for treatment of patients with C. difficile infection .Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words \"believes,\" \"anticipates,\" \"plans,\" \"expects,\" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 199","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acurx-pharmaceuticals-present-alliance-global-113000315.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-pharmaceuticals-present-alliance-global-113000315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4194","BK4137","BK4139","VRE","BK4563","HCSG","ACXP","BK4539"],"gpt_icon":0},{"id":"2528971583","title":"Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2528971583","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528971583?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:30","pubTimestamp":1744889400,"startTime":"0","endTime":"0","summary":"About Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum  that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC , inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus , vancomycin resistant Enterococcus , drug- resistant Streptococcus pneumoniae  and B. anthracis . Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials as soon as possible. The Company's preclinical pipeline includes development o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/indian-patent-office-grants-acurx-113000595.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indian-patent-office-grants-acurx-113000595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRE","ACXP","BK4194","BK4109","BK4563","BK4139","BK4539","DNA"],"gpt_icon":0},{"id":"2528227482","title":"New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2528227482","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528227482?lang=en_us&edition=fundamental","pubTime":"2025-04-17 00:45","pubTimestamp":1744821900,"startTime":"0","endTime":"0","summary":"NEW YORK CITY, NEW YORK / ACCESS Newswire / April 16, 2025 / New to The Street, a premier business television and media platform, is proud to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc.  for a new 6-month strategic campaign. The series will include long-form interviews airing as sponsored programming on Fox Business and Bloomberg Television, earned media placements, over 50 national commercials per month, and expanded visibility across New to The Street's 2.4M+ subscriber YouTube channel and digital networks.As a late-stage biopharmaceutical company pioneering a new class of antibiotics to combat drug-resistant infections, Acurx Pharmaceuticals continues to make headlines with its scientific breakthroughs and clinical developments. This renewed campaign will enhance Acurx's visibility among investors, healthcare professionals, and the broader biotech community.\"We're excited to expand our media footprint with New to The Street,\" said David P. Luci, Pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/street-renews-acurx-pharmaceuticals-nasdaq-164500720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4539","LU2210149790.SGD","NDAQ","LU2095319765.USD",".IXIC","IE00B64PRP62.GBP","TV","BK4112","ACXP","BK4563","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","BK4100","BK4588","BK4139"],"gpt_icon":0},{"id":"2526615407","title":"New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's  Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming","url":"https://stock-news.laohu8.com/highlight/detail?id=2526615407","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526615407?lang=en_us&edition=fundamental","pubTime":"2025-04-12 00:45","pubTimestamp":1744389900,"startTime":"0","endTime":"0","summary":"New Segment \"Market Bites\" Debuts with Chef John Doherty of BlackBarn Showcasing the Culinary Side of Business Leadership. NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / New to The Street, a leading financial media TV series, is excited to announce its Bloomberg Television broadcast this Saturday, April 12 at 6:30 PM ET, airing as sponsored programming. This week's episode features a dynamic group of innovators and executives transforming industries across healthcare, biotech, sustainability, and enzyme technology - with a special culinary segment connecting business and lifestyle.Segment Debut: \"Market Bites\"This week also marks the premiere of New to The Street's new culinary lifestyle segment, \"Market Bites,\" spotlighting renowned chefs who are also savvy entrepreneurs. In this debut, Chef John Doherty, the visionary behind BlackBarn in Manhattan, takes viewers inside his kitchen and mindset - blending flavor with business strategy in an inspiring interview filmed on l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/street-announces-bloomberg-television-lineup-164500675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SGTM","BIVI","QID","BK4581","LU0390134368.USD",".IXIC","RDZN","ACXP","PSQ","NVIW.SI","USAW.SI","TQQQ","TYL","TISI","BK4590","SQQQ","NQmain","BK4144","BK4539","QLD","BK4561","RDZNW","TSYW.SI","ET","USJW.SI","BK4585","BK4023","BK4120","MNQmain","BK4563","BK4588"],"gpt_icon":1},{"id":"2525110812","title":"Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2525110812","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525110812?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:55","pubTimestamp":1744120504,"startTime":"0","endTime":"0","summary":"Shares of Acurx Pharmaceuticals, Inc.  have been struggling lately and have lost 15.9% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal.What is a Hammer Chart and How to Trade It?If this is not enough, you should note that ACXP currently has a Zacks Rank #2 , which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-pharmaceuticals-acxp-may-bottom-135504915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","BK4139","ACXP","BK4539"],"gpt_icon":0},{"id":"2521253768","title":"Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2521253768","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521253768?lang=en_us&edition=fundamental","pubTime":"2025-03-22 00:00","pubTimestamp":1742572808,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals, Inc.  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Acurx Pharmaceuticals basically reflects positivity about its earnings outlook that could translate into buying pressure and an ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-pharmaceuticals-acxp-upgraded-buy-160008145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACXP"],"gpt_icon":0},{"id":"2520981360","title":"Acurx price target lowered to $5 from $14 at Alliance Global Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2520981360","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520981360?lang=en_us&edition=fundamental","pubTime":"2025-03-19 00:50","pubTimestamp":1742316618,"startTime":"0","endTime":"0","summary":"Alliance Global Partners lowered the firm’s price target on Acurx (ACXP) to $5 from $14 and keeps a Buy rating on the shares after the company repo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acurx-price-target-lowered-to-5-from-14-at-alliance-global-partners?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acurx-price-target-lowered-to-5-from-14-at-alliance-global-partners?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4563","ACXP","BK4139"],"gpt_icon":0},{"id":"2520623774","title":"Acurx Pharmaceuticals FY 2024 GAAP EPS $(0.87) Beats $(1.52) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520623774","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520623774?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:08","pubTimestamp":1742296102,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.52) by 42.76 percent. This is a 24.35 percent increase over losses of $(1.15) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44373161/acurx-pharmaceuticals-fy-2024-gaap-eps-0-87-beats-1-52-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Acurx Pharmaceuticals FY 2024 GAAP EPS $(0.87) Beats $(1.52) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP"],"gpt_icon":0},{"id":"2519804147","title":"Acurx Pharmaceuticals Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519804147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519804147?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:22","pubTimestamp":1741958528,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc  expected to post a loss of18cents a share - Earnings Preview Acurx Pharmaceuticals Inc ACXP.OQ ACXP.O is expected to report results on March 18 for the period ending Decembe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX19Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":50,"code":"91000000","status":"200"}]}}